Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
83.21
USD
-1.58 (-1.86%)
Official Closing Price
Updated: 7:21 PM EST, Mar 8, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All news about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
98
99
Next >
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investor Notice: Investigation over Potential Wrongdoing
Today 12:30 EST
San Diego, CA -- (SBWIRE) -- 03/08/2021 -- Certain directors of Sarepta Therapeutics, Inc are under investigation concerning potential breaches of fiduciary duties.
From
SBWire - Latest Press Releases
RSI Alert: Sarepta Therapeutics (SRPT) Now Oversold
March 05, 2021
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...
Tags
Stocks
From
Market News Video
Sarepta Therapeutics (SRPT) Q4 2020 Earnings Call Transcript
March 02, 2021
SRPT earnings call for the period ending December 31, 2020.
Tags
Market News
SRPT
From
Motley Fool
10 Stocks Moving In Monday's After-Hours Session
March 01, 2021
Gainers Zoom Video Communications (NASDAQ: ZM) shares are trading higher after the company reported better-than-expected Q4 EPS ...
Tags
TVTX
Trading Ideas
ZM
From
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
March 01, 2021
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 31.41% to $6.61 during Monday's after-market session. Trading volume for ...
Tags
SRPT
INVO
ARAY
From
Benzinga
Recap: Sarepta Therapeutics Q4 Earnings
March 01, 2021
Shares of Sarepta Therapeutics (NASDAQ:SRPT) decreased in after-market trading after the company reported Q4 results. Quarterly ...
Tags
SRPT
Market News
Earnings
From
Benzinga
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
March 01, 2021
From
GlobeNewswire News Releases
Earnings Scheduled For March 1, 2021
March 01, 2021
Companies Reporting Before The Bell • Athenex (NASDAQ:ATNX) is likely to report quarterly loss at $0.44 per share on ...
Tags
GAIA
XRAY
FGEN
From
Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
February 28, 2021
Most Food and Drug Administration decisions scheduled for February were positive, and more importantly five new molecular entities ...
Tags
pharmaceuticals
Market News
BLUE
From
Benzinga
The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings
February 27, 2021
Biotech stocks extended their losses in the week ended Feb. 26 amid continued weakness in the broader market. Earnings came in thick and ...
Tags
BOLT
BHVN
OPTN
From
Benzinga
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 26, 2021
From
GlobeNewswire News Releases
Earnings Preview: Sarepta Therapeutics
February 26, 2021
Sarepta Therapeutics (NASDAQ:SRPT) announces its next round of earnings this Monday, March 01. Here is Benzinga's ...
Tags
BZI/EP
Benzinga
Earnings
From
Benzinga
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
February 25, 2021
From
GlobeNewswire News Releases
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
February 25, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Tags
Offerings
GBT
APLS
From
Benzinga
Sarepta Therapeutics to Present at Upcoming Investor Conferences
February 24, 2021
From
GlobeNewswire News Releases
The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
February 24, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Tags
GTHX
RGEN
VBLT
From
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
February 23, 2021
During Tuesday's morning trading, 22 companies set new 52-week lows. Points of Interest: Viatris ...
Tags
BZI/52Weeks
MSP
IMRA
From
Benzinga
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021
February 22, 2021
From
GlobeNewswire News Releases
The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings
February 20, 2021
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before ...
Tags
ALIM
ICPT
EDIT
From
Benzinga
How Will Biden's Executive Orders Affect Your Healthcare Stocks?
February 08, 2021
The decisions could have both short- and long-term implications.
Tags
QDEL
LH
SRPT
From
Motley Fool
FBT's Underlying Holdings Could Mean 16% Gain Potential
February 05, 2021
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
February 04, 2021
Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company")(NASDAQ: SRPT). Such investors are advised to contact Robert S. Willoughby at...
From
PR Newswire
Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition
February 04, 2021
From
GlobeNewswire News Releases
Repligen Stock Doubled In 2020 — Why Covid Demand Is Fueling It
February 04, 2021
When it comes to coronavirus vaccines, think of Repligen as the man behind the curtain and RGEN stock as a tools powerhouse. Shares broke out of a cup base in January and hover in a buy zone.
From
Investor's Business Daily
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
February 01, 2021
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:...
From
PR Newswire
Sarepta Therapeutics Larger Than S&P 500 Component Kimco Realty
February 01, 2021
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Sarepta Therapeutics Inc (SRPT) was identified as having a larger market cap than the smaller end of the...
Tags
Stocks
From
Market News Video
Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates
January 31, 2021
Coming off a stellar year, when a record 53 new molecular entities were approved, 2021 has a lot to live up to. NMEs are a measure of ...
Tags
Biotech
SRPT
Penny Stocks
From
Benzinga
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 29, 2021
From
GlobeNewswire News Releases
Pfizer Stock 2021: A Lean, Mean, Covid-Fighting Machine?
January 22, 2021
Pfizer sees coronavirus vaccines as a "durable" business, one executive said recently. But don't expect Pfizer stock to be hung up on Covid-19 in 2021. The company sees plenty of catalysts.
From
Investor's Business Daily
Noteworthy Wednesday Option Activity: CALX, CCS, SRPT
January 20, 2021
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Calix Inc (CALX), where a total volume of 4,022 contracts has been traded thus far...
Tags
Stocks
From
Market News Video
< Previous
1
2
3
4
5
6
7
8
9
...
98
99
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.